The purified protein derivative (PPD) skin test has no predictive value for tuberculosis (TB) in Mycobacterium bovis bacillus Calmette-Guérin (BCG)-vaccinated individuals because of cross-reactive responses to nonspecific constituents of PPD. T cell responses to early-secreted antigenic target 6-kDa protein (ESAT-6) and the newly identified culture filtrate protein 10 (CFP-10), 2 proteins specifically expressed by M. tuberculosis (MTB) but not by BCG strains, were evaluated. Most TB patients responded to ESAT-6 (92%) or CFP-10 (89%). A minority of BCG-vaccinated individuals responded to both ESAT-6 and CFP-10, their history being consistent with latent infection with MTB in the presence of protective immunity. No responses were found in PPD-negative controls. The sensitivity and specificity of the assay were 84% and 100%, respectively, at a cutoff of 300 pg of interferon-g/mL. These data indicate that ESAT-6 and CFP-10 are promising antigens for highly specific immunodiagnosis of TB, even in BCG-vaccinated individuals.
H37Rv and BCG [3] have identified 1 region of difference, designated RD1, that was found to be present in all MTB and pathogenic M. bovis strains but lacking in all BCG vaccine strains and almost all environmental mycobacteria. One antigen encoded by RD1 is the early-secreted antigenic target 6-kDa protein (ESAT-6) [4, 5] , which is immunodominant in mice [6] . T cell responses to ESAT-6 can discriminate between cattle infected with M. bovis and cattle sensitized to environmental mycobacteria [7] . In previous studies of human pulmonary TB, T cell responses to ESAT-6 were observed in approximately half of the patients [8] [9] [10] . Recently, a second RD1-encoded protein, designated culture filtrate protein 10 (CFP-10), was identified [11] . Recent results indicate that this antigen is strongly recognized by T cells [12, 13] . In the present study, we evaluated T cell responses to ESAT-6 and CFP-10 in patients with TB in comparison with various control groups without TB, including BCG-vaccinated individuals.
Subjects and Methods

Subjects.
Thirty-seven TB patients aged years 45.9 ‫ע‬ 16.1 ( ; range, 12-70 years) were recruited at the Leiden Unimean ‫ע‬ SD versity Medical Center in Leiden or at the Rijnland Hospital in Leiderdorp, The Netherlands. The patients originated from Western Europe ( ), Africa ( ), Asia ( ), South America n = 20 n = 8 n = 4 ( ), or the Middle East ( ). The localization of TB was
), cutaneous ( ), or subcutaneous ( ). TB was n = 1 n = 1 n = 1 present at 11 site in 9 patients. We included patients before treatment was started, as well as patients during and after treatment, to evaluate the time course of immune responses. Patients infected with human immunodeficiency virus were excluded because cellmediated immunity to mycobacteria has been shown to be defective in the presence of low CD4 ϩ cell counts. Twelve individuals with documented PPD conversion after contact with contagious TB, 14 BCG-vaccinated subjects (10 of whom were PPD positive), and 8 healthy, PPD-negative, non-BCG-vaccinated subjects, including medical, nursing, and technical hospital personnel and relatives of TB patients, were recruited from various sources.
Antigens. Recombinant ESAT-6 (batch p432) and CFP-10 (batches 98-2 and 99-1) were expressed in Escherichia coli, as described elsewhere [4, 5, 11] . MTB H37Rv sonicate was provided by Dr. D. van Soolingen (National Institute of Public Health and Environment, Bilthoven, The Netherlands). The production of short-term culture filtrate (ST-CF) has been described elsewhere [14] .
Cellular stimulation assays.
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous blood by Ficoll-Hypaque density gradient centrifugation. Cells were frozen in RPMI 1640 (Gibco, Paisley, Scotland) supplemented with 0.04 mM/mL glutamine, 20% fetal calf serum, and 10% dimethyl sulfoxide. For the experiments, PBMC ( per well) were in-5 1.5 ϫ 10 cubated in round-bottom microtiter wells in the presence or absence of antigen in 200 mL of Iscoves modified Dulbecco's medium (Gibco), supplemented with 10% pooled human AB serum, 40 U/ mL penicillin, and 40 mg/mL streptomycin in triplicate at 37ЊC in humidified air containing 5% CO 2 . The final concentrations of the antigens used were as follows: ESAT-6, 1 and 10 mg/mL; CFP-10, 0.5 and 5 mg/mL; MTB sonicate and ST-CF, 0.1 and 1 mg/mL each. Supernatants for interferon-g (IFN-g) determinations, as the readout of T cell activation, were collected at days 3 and 6 (50 mL/well) and pooled per triplicate. Responses at day 6 were optimal and were used for the analysis.
IFN-g production. IFN-g was measured with a standard ELISA technique (U-CyTech, Utrecht, The Netherlands). The detection limit of the assay was 20 pg of IFN-g/mL. IFN-g values in unstimulated cultures were typically undetectable, except in 15 (11%) of 136 unstimulated triplicates with a median concentration of 62 pg/mL. Detectable values were subtracted from the value in stimulated cultures.
Statistical analysis. Differences between responses were tested with the nonparametric Kruskal-Wallis and Mann-Whitney tests. Correlation of individual responses to different antigens was analyzed by Spearman correlation. Receiver-operator characteristic (ROC) curves were constructed to describe the relation between the sensitivity and specificity at varying cutoff levels. All statistical analyses were 2 sided, and P values !.05 were considered statistically significant.
Results
Responses to MTB sonicate and ST-CF.
T cell responses to MTB sonicate in TB patients (figure 1A) were significantly higher than those in PPD-negative controls without BCG vaccination but were not different from those in BCG-vaccinated or PPD-converted individuals. T cell responses to ST-CF of TB patients (figure 1B) were significantly higher than the responses of the other groups.
TB patients and control groups respond differently to ESAT-6 and CFP-10. Responses to ESAT-6 (figure 1C) and CFP-10 (figure 1D) differed highly significantly between the study groups ( for comparison of all groups). Individual P ! .0001 responses to ESAT-6 and CFP-10 were highly correlated (r = ; 95% confidence interval, 0. Nine of 12 individuals with documented PPD conversion after contact with contagious TB responded to ESAT-6; 4 of those 9 individuals also responded to CFP-10. Five (36%) of 14 BCG-vaccinated persons responded to ESAT-6, and 5 (36%) of 14 responded to CFP10, with concordant responses in 4, all of whom were PPD positive and had a history compatible with past exposure to MTB. None of them had ever had clinical signs suggestive of TB. None of the BCG-vaccinated individuals who were nonresponsive to ESAT-6 and CFP-10 had recognized exposure to MTB, but all had been vaccinated with BCG because they were in high-risk jobs. None of the PPD-negative, non-BCG-vaccinated controls responded to ESAT-6 or CFP-10.
Cutoff level to define a positive test result. ROC curves were constructed from the responses to MTB sonicate (figure 2A), ST-CF (figure 2B), and the individual maximum of responses to ESAT-6 and CFP-10 ( figure 2C ), comparing all 37 TB patients with BCG-vaccinated and PPD-negative, non-BCG-vaccinated controls, taken together as a group without TB. At a cutoff level of 300 pg/mL, the sensitivity of the individual maximum of the responses to ESAT-6 and CFP-10 was 84%, and the specificity was 100%. ROC analysis limited to TB patients who were tested before anti-TB treatment was initiated (n = ) resulted in similar ROC curves as those based on all 37 TB 13 patients ( figure 2D through 2F) , indicating that the postinfection interval was not a major determinant of the overall test performance.
Discussion
In the present study, T cell responses to ESAT-6 and the newly identified RD1-encoded antigen CFP-10 are shown to ) but not different from those of BCG-vaccinated (∇) or PPD-converted (᭡) individuals. T cell responses of TB patients to short-term P = .0005 culture filtrate (ST-CF) (B) were significantly higher than those of each of the other groups ( , , and for the comparisons P = .0002 P = .01 P = .007 with PPD-negative, BCG-nonvaccinated; BCG-vaccinated; and PPD-converted subjects, respectively). Interferon-g (IFN-g) production in response to early-secreted antigenic target 6-kDa protein (ESAT-6) (C) and culture filtrate protein-10 (CFP-10) (D) was significantly higher in TB patients than in BCG-vaccinated and PPD-negative, non-BCG-vaccinated controls ( for all comparisons). Comparison of TB patients and P ! .0001 individuals with documented PPD conversion after exposure to MTB demonstrated significant differences in responses to CFP-10 ( ) and P = .02 differences of borderline significance in responses to ). Statistical comparison between groups was performed using the Mann-P = .07 Whitney U test. Short lines represent geometric mean responses for the groups. Dotted lines represent detection limit of the IFN-g ELISA (20 pg/mL).
be highly sensitive and specific for discrimination between patients with TB disease and noninfected individuals and to be significantly more specific than responses to the complex antigens MTB sonicate and ST-CF. Most patients with active or treated TB in our study responded to the specific antigens ESAT-6 or CFP-10 or both. The higher sensitivity of responses to ESAT-6 than that found in previous studies [8] [9] [10] could be related to differences in test conditions. Our results strongly support larger prospective studies to establish the actual predictive value of T cell responses to ESAT-6 and CFP-10 in patients suspected to have TB disease, and we recently started such a study. Moreover, ongoing follow-up studies of healthy, untreated, PPD-positive TB contacts indicate that responses to ESAT-6 are associated with the risk of developing active TB (authors' unpublished observations). Factors contributing to the observed variability of responses to ESAT-6 and CFP10 in the TB patients could include mycobacterial load, antigen expression level of MTB strains, and genetically based characteristics of antigen processing and immune responsiveness in the host, including cytokine secretion profiles or polymorphisms of HLA or cytokine receptors.
The majority of the PPD-converted individuals and several of the BCG-vaccinated subjects in our study responded to ESAT-6, and some also responded to CFP-10, presumably as a result of latent infection with MTB. Latent infection with MTB is 10 times more frequent than active TB, with global prevalence rates estimated to amount to one-third of the world's population. Subclinical or latent infection with MTB was the presumed cause of T cell responses to ESAT-6 observed in many Ethiopian control subjects in a previous study [8] . Today, half Including only those TB patients from whom samples were taken before anti-TB chemotherapy had been instituted ( ) yielded ROC curves (D-F) n = 13 similar to those including all 37 patients. The ROC curves end at a cutoff value equal to the detection limit of the ELISA (20 pg/mL), because interferon-g production was below the detection limit in a number of subjects.
of all TB patients in Western countries originate from areas with highly endemic TB where BCG vaccination is routine practice. It must therefore be expected that latent infection with MTB, accompanied by T cell responses to MTB-specific antigens, can occur in relevant control groups.
The PPD skin test is technically simple, can be produced at low cost, and is more or less reproducible if performed by skilled personnel [1] . Yet the PPD skin test lacks specificity in BCGvaccinated individuals, as was confirmed in the present study, in which responses to MTB sonicate were similar and those to ST-CF were only moderately different in TB patients and BCGvaccinated individuals. Skin tests with PPDs derived from nontuberculous mycobacteria were of variable use for discrimination between TB and infection with atypical mycobacteria [15] . The requirements for an in vitro T cell assay are more complex and include highly purified MTB-specific antigens and facilities for cell-culture and cytokine assays, limiting its use as a routine diagnostic tool. However, antigens that appear specific in an in vitro T cell assay could be evaluated in a skin test. This preferably would be a test based on a combination of several specific antigens; in animal models of TB, the sensitivity of a skin test based on recombinant antigens was reported to increase with the number of antigens [16] .
The functions of ESAT-6 and CFP-10 remain to be elucidated, but conceivably they contribute to virulence, because RD1 was deleted early during the process of attenuation of pathogenic M. bovis to essentially avirulent BCG [3] . Immunization of mice with DNA encoding for ESAT-6 conferred moderate protection against airborne experimental TB, although substantially less than that achieved by BCG vaccination [17] . ESAT-6 and CFP-10 probably have related functions, because both genes are part of the same operon, and transcription is regulated under the same promoter gene [11] . An indirect indication of coexpression of ESAT-6 and CFP-10 is our observation that individual responses to ESAT-6 and CFP-10 were highly correlated ( ). P ! .0001
In conclusion, in vitro T cell responses to ESAT-6 and CFP-10 appear to be highly sensitive and specific for detection of infection with MTB and to be significantly more discriminative than responses to the complex antigens, especially in BCGvaccinated individuals. ESAT-6 and CFP-10 are therefore interesting and highly promising antigens to include in future studies aimed at specific immunodiagnosis of TB.
